FK866 (APO866): Non-Competitive NAMPT Inhibitor for Cancer Metabolism Research

Executive Summary:
FK866 (APO866) is a highly specific, non-competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD biosynthesis pathway (Ji et al., 2025). It exhibits a Ki of 0.4 nM and IC50 values as low as 0.09 nM in cellular assays. FK866 induces selective, caspase-independent cytotoxicity in acute myeloid leukemia (AML) cells by depleting NAD and ATP, while sparing normal hematopoietic progenitors (see Evidence). The compound's antitumor efficacy is validated in mouse xenograft models, offering a translational tool for cancer metabolism research. APExBIO supplies FK866 (A4381) with validated solubility and storage parameters for experimental reproducibility (product page).

Biological Rationale

Nicotinamide adenine dinucleotide (NAD) is essential for cellular metabolism, DNA repair, and survival in both normal and malignant cells (Ji et al., 2025). NAMPT catalyzes the rate-limiting step in the salvage pathway of NAD biosynthesis. Cancer cells, especially hematologic malignancies like AML, show increased reliance on NAMPT activity for rapid proliferation. Inhibition of NAMPT leads to NAD and ATP depletion, disrupting energy metabolism and inducing cell death. Targeting NAMPT is thus a rational strategy for selectively impairing cancer cell viability while minimizing effects on normal cells. Recent research also links NAMPT to processes such as vascular senescence and DNA repair, further broadening its relevance (DOI).

Mechanism of Action of FK866 (APO866)

FK866 is a highly specific, non-competitive inhibitor of NAMPT, binding outside the enzyme’s active site. It achieves a Ki of 0.4 nM under standard in vitro conditions (buffer pH 7.4, 25°C). FK866 blocks the conversion of nicotinamide to nicotinamide mononucleotide (NMN), leading to a rapid drop in intracellular NAD and subsequently ATP. This energy crisis induces cell death in cancer cells through a caspase-independent pathway involving mitochondrial membrane depolarization. FK866 also promotes autophagy, which is dependent on new protein synthesis (see mechanistic overview). Unlike classical apoptosis, FK866-induced cell death does not require caspase activation, distinguishing its action profile in cancer metabolism targeting.

Evidence & Benchmarks

• FK866 inhibits NAMPT with a Ki of 0.4 nM and IC50 values ranging from 0.09 nM (enzyme assay) to 27.2 nM (cellular context) under standard conditions (APExBIO product docs).
• In AML cell lines, FK866 induces selective cytotoxicity, sparing normal hematopoietic progenitors (IC50 < 10 nM, 48–72h exposure, 5% CO₂, 37°C) (internal article).
• Cell death occurs via caspase-independent pathways, confirmed by lack of PARP cleavage and mitochondrial membrane depolarization assays (internal article).
• FK866 promotes autophagy in AML cells, requiring de novo protein synthesis as shown by cycloheximide co-treatment experiments (Ji et al., 2025).
• In mouse xenograft models of AML and lymphoblastic lymphoma, FK866 administration (10 mg/kg i.p., daily) prevented tumor growth and improved survival (median survival extension: 30%, p < 0.01) (DOI).
• FK866 is insoluble in water but soluble in DMSO (≥19.6 mg/mL) and ethanol (≥49.6 mg/mL) at 20°C; stock solutions remain stable at -20°C for several months (product page).

Applications, Limits & Misconceptions

FK866 (APO866) is widely used as a research tool for dissecting cancer cell metabolism, particularly in hematologic malignancies such as AML. Its selectivity for malignant cells and non-competitive inhibition mechanism make it suitable for studies on NAD-dependent processes, DNA damage response, and mitochondrial function. FK866 is also used in vascular biology, where NAMPT is implicated in senescence and aging (Ji et al., 2025).

This article extends the mechanistic detail found in Targeting Cancer Metabolism with FK866 (APO866) by providing up-to-date quantitative benchmarks and clarifying caspase-independence. For workflow protocols and troubleshooting, see FK866: Precision NAMPT Inhibition for Reliable Hematologic Models—this piece updates stability and solubility recommendations based on recent product data.

Common Pitfalls or Misconceptions

• FK866 is not a pan-cytotoxic agent; its action is selective for cells with high NAMPT dependence (e.g., AML).
• It does not induce classical apoptosis—caspase inhibitors do not prevent FK866-mediated cell death.
• FK866 is insoluble in water; improper solvent use (e.g., aqueous buffers) leads to precipitation and loss of activity.
• Long-term storage of FK866 solutions (> several months) at higher than -20°C can result in compound degradation.
• FK866 does not inhibit PARP1 directly; its effects on DNA repair are mediated through NAD depletion (DOI).

Workflow Integration & Parameters

FK866 is supplied by APExBIO as a solid under the chemical name (E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-pyridin-3-ylprop-2-enamide, with molecular formula C₂₄H₂₉N₃O₂ (product specs). To prepare stock solutions, dissolve in DMSO (≥19.6 mg/mL) or ethanol (≥49.6 mg/mL) at room temperature. For cell-based assays, dilute stocks into culture media to achieve working concentrations (0.1–100 nM) immediately before use. Store solid at -20°C; solutions at -20°C for short-term, avoid freeze-thaw cycles. For in vivo models, typical dosing is 10 mg/kg i.p. daily; consult protocol for species and formulation compatibility. FK866 is best suited for experiments requiring precise modulation of NAD metabolism and measurement of cell viability, apoptosis-independent death, or metabolic flux. For detailed protocols, see FK866: NAMPT Inhibitor Workflows for AML Research.

Conclusion & Outlook

FK866 (APO866) represents a validated, highly potent tool for dissecting cancer metabolism and studying the role of NAD biosynthesis in disease. Its ability to induce selective, caspase-independent cell death in AML, robust antitumor activity in xenograft models, and well-characterized solubility/stability profile position it as an indispensable reagent for academic and translational research. Future studies may leverage FK866 to explore emerging roles of NAMPT in aging, DNA repair, and metabolic vulnerabilities across cancer subtypes (Ji et al., 2025).